First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announces that the company has signed a non-binding term sheet for a business combination with ImmunogenX, a clinical-stage biotherapeutics company developing Phase 3-ready latiglutenase, a potentially first-in-class, targeted, oral biotherapeutic for celiac disease.
Read the full article: First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company //
Source: https://www.globenewswire.com/news-release/2023/12/18/2797607/0/en/First-Wave-BioPharma-Announces-Entry-into-Term-Sheet-for-Business-Combination-with-ImmunogenX-Establishing-a-Leading-Late-Stage-GI-Focused-Biopharmaceutical-Company.html